Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 6, 2015, Pages 1032-1039

  Xu, Li ^a,b   Gao, Hengjun ^a,b,c   Huang, Junting ^a,b   Wang, Haoyuan ^a,b   Zhou, Zhongguo ^a,b   Zhang, Yaojun ^a,b   Li, Shaohua ^a,b   Chen, Minshan ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Colorectal Surgery   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Antiviral therapy; Hepatocellular carcinoma; Sorafenib; Survival

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; SORAFENIB; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; NUCLEOSIDE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG COMBINATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; NUCLEOSIDES; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SURVIVAL RATE;

EID: 84928348150     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12910     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
5. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
6. Kim BK, Park JY, Kim Y etal. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008; 28: 393-401.
7. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 1663-1673.
8. Wu CY, Chen YJ, Ho HJ etal. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914.
9. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
10. Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. [Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2013; 21: 96-100.
11. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
12. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 2000; 92: 205-216.
13. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
14. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 2014; 11: 525-535.
15. Guan YS, He Q. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opin. Pharmacother. 2011; 12: 303-313.
16. Choi GH, Shim JH, Kim MJ etal. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013; 269: 603-611.
17. Liu L, Chen H, Wang M etal. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS ONE 2014; 9: e91124.
18. Zhu K, Chen J, Lai L etal. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study. Radiology 2014; 272: 284-293.
19. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 2006; 101: 1797-1803.
20. Yeh CT, So M, Ng J etal. Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 2010; 52: 1922-1933.
21. An HJ, Jang JW, Bae SH etal. Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2010; 25: 1876-1882.
22. Wu CY, Chen YJ, Ho HJ etal. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914.
23. Hann HW, Coben R, Brown D etal. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014; 3: 390-396.
24. Kuzuya T, Katano Y, Kumada T etal. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1929-1935.
25. Yoo DJ, Kim KM, Jin YJ etal. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J. Gastroenterol. Hepatol. 2011; 26: 145-154.
26. He YF, Li YH, Wang FH etal. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann. Hematol. 2008; 87: 481-485.
27. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin. Gastroenterol. Hepatol. 2006; 4: 1076-1081.
28. Zhao WGY, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 1226-1233.22.
29. Zhang QB, Sun HC, Zhang KZ etal. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS ONE 2013; 8: e55945.